Tower Research Capital (TRC)’s Apimeds Pharmaceuticals US APUS Stock Holding History

Tower Research Capital (TRC)’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.5K	Buy	+166	New	+$2.26K	﹤0.01%	4808
2026 Q1	–	Sell	-1	Closed	-$16	–	5716
2025 Q4	$16	Buy	+1	New	+$21	﹤0.01%	5103
2025 Q3	–	Sell	-315	Closed	-$5.55K	–	5765
2025 Q2	$5.55K	Buy	+315	New	+$5.68K	﹤0.01%	4175

Other funds holding APUS

HTHT

Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s APUS Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Apimeds Pharmaceuticals US (APUS) in Q2 2026: 166 shares worth $1.5K. The stake represents ﹤0.01% of the portfolio and ranks #4808 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in APUS as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in APUS in Q2 2025 and has held it in 3 quarters since. The position peaked at $5.55K in Q2 2025. 7 funds tracked by Wall St. Rank hold APUS as of Q2 2026.

Tower Research Capital (TRC) held 166 shares of Apimeds Pharmaceuticals US worth $1.5K as of Q2 2026.
Apimeds Pharmaceuticals US was a new Tower Research Capital (TRC) position in Q2 2026.
Apimeds Pharmaceuticals US made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4808 holding.
Tower Research Capital (TRC) first reported a position in Apimeds Pharmaceuticals US in Q2 2025 and has held it in 3 quarters since.
Tower Research Capital (TRC)'s Apimeds Pharmaceuticals US position peaked at $5.55K in Q2 2025.
7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.